Your browser doesn't support javascript.
loading
Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
Keller, Christian W; Ruck, Tobias; McHugh, Donal; Pfeuffer, Steffen; Gross, Catharina C; Korsukewitz, Catharina; Melzer, Nico; Klotz, Luisa; Meuth, Sven G; Münz, Christian; Nimmerjahn, Falk; Wiendl, Heinz; Lünemann, Jan D.
Afiliação
  • Keller CW; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Ruck T; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • McHugh D; Laboratory of Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Pfeuffer S; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Gross CC; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Korsukewitz C; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Melzer N; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Klotz L; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Meuth SG; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Münz C; Laboratory of Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Nimmerjahn F; Department of Biology, Institute of Genetics, University of Erlangen-Nürnberg, Erlangen, Germany.
  • Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Lünemann JD; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Ann Clin Transl Neurol ; 6(12): 2586-2594, 2019 12.
Article em En | MEDLINE | ID: mdl-31682087
ABSTRACT
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Receptores de IgG / Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Receptores de IgG / Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article